Giant-cell tumor of bone with pulmonary metastases.

Bertoni, Franco; Present, David; Enneking, William F.

doi:10.2106/00004623-198567060-00011

Cited by 153 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of pulmonary metastasis in our collective counts 3.3% and is in accordance with previous reports (Bertoni et al 1985(Bertoni et al , 1988Cheng and Johnston 1997;Goldenberg et al 1970;Kay et al 1994;Masui et al 1998;Osaka et al 1997;Rock et al 1984;Sanjay and Kadhi 1998;Siebenrock et al 1998;Tubbs et al 1992). Interestingly the gender distribution is contrary to non-metastasizing tumors.…”

Section: Pulmonary Metastasessupporting

confidence: 93%

“…Local recurrence is accompanied by an increased risk of so called 'benign' pulmonary metastases (Bertoni et al 1985;Bertoni et al 1988;Campanacci et al 1987;Cheng and Johnston 1997;Dominkus et al 2006;Goldenberg et al 1970;Kay et al 1994;Maloney et al 1989;McDonald et al 1986;Osaka et al 1997;Rock et al 1984;Sanjay and Kadhi 1998;Siebenrock et al 1998;Tubbs et al 1992).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Giant cell tumor of bone: treatment and outcome of 214 cases

Balke

Schremper

Gebert

et al. 2008

J Cancer Res Clin Oncol

377

414

View full text Add to dashboard Cite

The combination of all adjuncts (PMMA, burring, H(2)O(2) - n = 42) reduces the likelihood of recurrence by the factor 28.2 compared to curettage only and therefore should be recommended as a standard treatment. If the tumor reaches close to the articulating surface a subchondral bone graft (n = 42) can be performed without risking a higher recurrence rate. We add seven cases of pulmonary metastases and two cases of multicentricity to the literature. Bisphosphonates and interferon alpha may have a beneficial effect.

show abstract

Section: Pulmonary Metastasessupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Giant cell tumor of bone: treatment and outcome of 214 cases

Balke

Schremper

Gebert

et al. 2008

J Cancer Res Clin Oncol

377

414

View full text Add to dashboard Cite

show abstract

“…Therefore, the pathogenesis of multiple benign lesions is still a matter of debate [22]. Multicentric GCT is considered to be either a genuine multifocal disease [4] or the result of local or distant spread of a solitary initial lesion [6,32].…”

Section: Introductionmentioning

confidence: 99%

Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study

et al. 2003

View full text Add to dashboard Cite

Multicentric giant-cell tumors of the bone (GCTs) are rare. Little is known about the mechanisms by which these tumors spread and how 1% of GCT turn out to be multicentric. We report the case of a 19-year-old woman with metachronous multiple and recurrent GCTs that were unusual in their pattern of progression along the right lower limb over a 23-year period. Histology showed no evidence of malignant transformation. The treatment was repeated curettage and packing with cement. This did not permit a wide surgical margin, but avoided amputation and preserved full limb function. We tested the proliferation index marker Ki-67 in the tumor specimens. Ki-67 expression was limited to the mononuclear cell component of the tumors. The proliferation index was similar in each new tumor and higher in recurrences for each location. In this case, proliferation was initially low in the new tumor location, despite the time difference and independent from the initial clone evolution. Proliferation index increased in recurrent GCTs after marginal margin resection.

show abstract

“…It has been estimated that there is a sixfold increase in the risk of lung metastases after a local recurrence [71]. These findings have been supported by previous case series [57,60,71]. Follow-up chest radiographs have been recommended, particularly for lesions involving the hand [28].…”

Section: Postoperative Imagingmentioning

confidence: 76%

“…It has been estimated that the overall risk of metastatic spread from GCTOB is approximately 1-9% [10,[57][58][59][60][61][62]. Overall, the mean interval between the diagnosis of the primary tumour and the detection of lung metastases is between 16 and 49 months [30,57].…”

Section: Metastatic Potentialmentioning

confidence: 99%

Giant-cell tumours of bone of the hand and wrist: a review of imaging findings and differential diagnoses

James

Davies

2005

Eur Radiol

View full text Add to dashboard Cite

Giant-cell tumour of bone (GCTOB) is a benign, locally aggressive, primary bone tumour. Involvement of the distal radius accounts for between 10 and 12% of cases of GCTOB, with the bones of the hand and wrist being rarely affected. GCTOB most commonly affects skeletally mature patients between the ages of 20 and 40 years, with the peak incidence being in the third decade. Women are affected slightly more commonly than men. GCTOB involving the bones of the hand most commonly occurs in a central location, which differs from the usual eccentric location seen in GCTOB at other sites. The radiographic features of GCTOB in the hand and wrist are presented. The role of bone scintigraphy, computed tomography and magnetic resonance imaging is discussed. Evaluation of the postoperative patient is also addressed, including the role of dynamic contrast-enhanced magnetic resonance imaging. A comprehensive review of the potential differential diagnoses that should be considered when GCTOB is suspected in the hand and wrist is also presented.

show abstract

Giant-cell tumor of bone with pulmonary metastases.

Cited by 153 publications

References 0 publications

Giant cell tumor of bone: treatment and outcome of 214 cases

Giant cell tumor of bone: treatment and outcome of 214 cases

Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study

Giant-cell tumours of bone of the hand and wrist: a review of imaging findings and differential diagnoses

Contact Info

Product

Resources

About